NDC 25021-400-30 Heparin Sodium

Heparin Sodium

NDC Package Code 25021-400-30

The NDC Code 25021-400-30 is assigned to a package of 25 vial in 1 carton > 30 ml in 1 vial of Heparin Sodium, a human prescription drug labeled by Sagent Pharmaceticals. The product's dosage form is injection, solution and is administered via intravenous; subcutaneous form.

Field Name	Field Value
NDC Code	25021-400-30
Package Description	25 VIAL in 1 CARTON > 30 mL in 1 VIAL
Proprietary Name	Heparin Sodium What is the Proprietary Name? The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name	Heparin Sodium What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
11-Digit NDC Billing Format	25021040030 NDC Format for Billing For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit	ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Product Type	Human Prescription Drug What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name	Sagent Pharmaceticals
Dosage Form	Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route(s)	Intravenous - Administration within or into a vein or veins. Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL. Intravenous - Administration within or into a vein or veins. Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)	HEPARIN SODIUM 1000 [USP'U]/mL HEPARIN SODIUM 1000 [USP'U]/mL
Pharmacological Class(es)	Anti-coagulant - [EPC] (Established Pharmacologic Class) Heparin - [CS] Unfractionated Heparin - [EPC] (Established Pharmacologic Class) Anti-coagulant - [EPC] (Established Pharmacologic Class) Heparin - [CS] Unfractionated Heparin - [EPC] (Established Pharmacologic Class)
Sample Package	No Sample Package? This field Indicates whether this package is a sample packaging or not.
Marketing Category	ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number	ANDA090808 What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date	07-01-2014 What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
Start Marketing Date	02-29-2020 What is the End Marketing Date? This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.

NDC Code Structure

25021 - Sagent Pharmaceticals
- 25021-400 - Heparin Sodium
  - 25021-400-30 - 25 VIAL in 1 CARTON

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

NDC HCPCS Crosswalk

This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

NDC 25021-400-30 HCPCS crosswalk information with package details and bill units information.

NDC Billing Code	HCPCS Code	HCPCS Code Desc.	Dosage	Package Size	Package Quantity	Billable Units	Billable Units / Pkg
25021040030	J1644	Inj heparin sodium per 1000u	1000 UNITS	30	25	30	750

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for Heparin Sodium with product NDC 25021-400.

NDC Package Code	Package Description
25021-400-01	25 VIAL in 1 CARTON > 1 mL in 1 VIAL
25021-400-10	25 VIAL in 1 CARTON > 10 mL in 1 VIAL
25021-400-66	25 VIAL in 1 CARTON > 1 mL in 1 VIAL
25021-400-67	25 VIAL in 1 CARTON > 10 mL in 1 VIAL

* Please review the disclaimer below.

Previous Code
25021-400

Next Code
25021-401